熱門資訊> 正文
OCGN、DNMR和DERM均为市前涨幅股
2024-03-26 20:33
- Gainers: Stoke Therapeutics (STOK) +95% Q4 earnings call release
- Check-Cap (CHEK) +47% jumps on Nobul AI business combination.
- Mesoblast (MESO) +30% gains as FDA backs regulatory plans for cell therapy.
- Krispy Kreme (DNUT) +23% plan to expand partnership across the U.S..
- Trump Media & Technology Group (DJT) +18% soars 20% ahead of Nasdaq debut today.
- Praxis Precision Medicines (PRAX) +19% Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients.
- Invivyd (IVVD) +18%.
- Viking Therapeutics (VKTX) +16% gains on early data for oral weight loss therapy.
- Sutro Biopharma (STRO) +15% FY earnings call release
- X.T.L. Biopharmaceuticals (XTLB) +13%.
- Reddit (RDDT) +11% roars back as shares jump 30% on Monday, adds more post-market.
- Journey Medical (DERM) +10%.
- Forge Global Holdings (FRGE) +8%.
- Perimeter Solutions (PRM) +8%.
- Cadeler (CDLR) +8%.
- Hempacco (HPCO) +8% partners with Gumbo Brands to launch cannabinoid-infused gummies.
- Nuvation (NUVB) +8% falls after AnHeart Therapeutics acquisition news.
- Sunnova Energy International (NOVA) +7% selected by Home Depot as exclusive solar, battery storage provider.
- Biohaven Ltd (BHVN) +7% gains on early data for oral weight loss therapy.
- Advantage Solutions (ADV) +6%.
- Ocugen (OCGN) +6%.
- Intelligent Group (INTJ) +6%.
- McCormick (MKC) +6% trades higher after margins expand in Q1.
- Danimer Scientific (DNMR) +6%.
More on premarket gainers & stock
- Journey Medical Corporation (DERM) Q4 2023 Earning Call Transcript
- Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues
- Ocugen shares make gains after US court dismisses class action lawsuits
- Ocugen hits a 52-week high after decision to lower quorum requirement
- Seeking Alpha’s Quant Rating on Journey Medical
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。